Patents by Inventor Ben A. Barres
Ben A. Barres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091220Abstract: The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediate neuronal and/or oligodendrocyte cell death in the subject.Type: ApplicationFiled: March 3, 2022Publication date: March 21, 2024Inventors: Shane LIDDELOW, Kevin GUTTENPLAN, Ben BARRES (Deceased)
-
Patent number: 10494602Abstract: Human pluripotent stem cells are differentiated in vitro into human cortical spheroids (hCS), which contain astrocytes, as well as cortical progenitors and neurons for use in analysis, screening programs, and the like.Type: GrantFiled: May 18, 2016Date of Patent: December 3, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Steven Sloan, Anca M. Pasca, Ben A. Barres, Sergiu P. Pasca
-
Publication number: 20190248885Abstract: Provided are methods of modulating neuronal and/or oligodendrocyte survival. The subject methods relate to preventing neuronal and/or oligodendrocyte death or increasing neuron or oligodendrocyte death. Also provided are neuroprotective compositions and neurotoxic compositions. Methods of identifying neurotoxins, methods of identifying neurotoxin inhibitors and methods of identifying neurotoxin conditions in a subject are also provided.Type: ApplicationFiled: October 25, 2017Publication date: August 15, 2019Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Shane Antony Liddelow, Kevin Guttenplan, Ben A. Barres
-
Patent number: 10330671Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: November 11, 2016Date of Patent: June 25, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 10240156Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: GrantFiled: July 28, 2016Date of Patent: March 26, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
-
Patent number: 10093898Abstract: Compositions and methods are provided for the purification of astrocytes from biological samples or from in vitro cultures. An advantage of the methods of the invention is the ability to isolate astrocytes in a quiescent state, which allows analysis of the cells in a more natural state.Type: GrantFiled: May 18, 2016Date of Patent: October 9, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ye Zhang, Steven Sloan, Ben A. Barres
-
Publication number: 20170059559Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: November 11, 2016Publication date: March 2, 2017Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20160340648Abstract: Compositions and methods are provided for the purification of astrocytes from biological samples or from in vitro cultures. An advantage of the methods of the invention is the ability to isolate astrocytes in a quiescent state, which allows analysis of the cells in a more natural state.Type: ApplicationFiled: May 18, 2016Publication date: November 24, 2016Inventors: Ye Zhang, Steven Sloan, Ben A. Barres
-
Patent number: 9493555Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: March 15, 2016Date of Patent: November 15, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20160326534Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: ApplicationFiled: July 28, 2016Publication date: November 10, 2016Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Alexander H. Stephen, Beth A. Stevens
-
Patent number: 9480658Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: GrantFiled: August 15, 2012Date of Patent: November 1, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
-
Patent number: 9388238Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: June 26, 2015Date of Patent: July 12, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9382314Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: June 26, 2015Date of Patent: July 5, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9382313Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: June 26, 2015Date of Patent: July 5, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20160185844Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: March 15, 2016Publication date: June 30, 2016Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20150368325Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20150368324Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20150368326Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9149444Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: December 14, 2011Date of Patent: October 6, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 8895507Abstract: Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis.Type: GrantFiled: April 16, 2008Date of Patent: November 25, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Cagla Eroglu